ストックスクリーナーアプリを入手
7.86
6.22%
0.46
アフターアワーズ：
7.86
前日終値:
$7.40
開ける：
$7.48
24時間の取引高:
726.03K
Relative Volume:
1.21
時価総額：
$427.74M
収益：
$3.32M
当期純損益:
$-156.76M
株価収益率:
-2.7086
EPS:
-2.9019
ネットキャッシュフロー:
$-140.13M
1週間 パフォーマンス:
+13.58%
1か月 パフォーマンス:
+11.49%
6か月 パフォーマンス:
-72.01%
1年 パフォーマンス:
-28.42%
1日の値動き範囲:
$7.32
$8.00
1週間の範囲:
$6.81
$8.00
52週間の値動き範囲:
$5.85
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
Compare UPB vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
7.86 | 402.71M | 3.32M | -156.76M | -140.13M | -2.9019 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-27 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-12-18 | 開始されました | Mizuho | Outperform |
| 2025-11-18 | 開始されました | Evercore ISI | Outperform |
| 2025-10-14 | 開始されました | Truist | Buy |
| 2024-11-05 | 開始されました | JP Morgan | Overweight |
| 2024-11-05 | 開始されました | Piper Sandler | Overweight |
| 2024-11-05 | 開始されました | TD Cowen | Buy |
| 2024-11-05 | 開始されました | William Blair | Outperform |
すべてを表示
Upstream Bio Inc (UPB) 最新ニュース
Price to book forward of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
UPBUpstream Bio Inc Dividends - Finviz
Here's Why We're Watching Upstream Bio's (NASDAQ:UPB) Cash Burn Situation - Moomoo
Enterprise value to EBIT forward of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
UpStream Bio(UPB) Stock Options Chain | Quotes & News - Moomoo
Why Did UPB Stock Plunge 40% Today? - Stocktwits
UPB News | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Upstream Bio, Inc. (UPB) reports Q1 loss, beats revenue estimates - MSN
Upstream Bio, Inc. Actuals & Estimates (NASDAQ:UPB) - TradingView
Upstream Bio, Inc. Actuals & Estimates (BOATS:UPB) - TradingView
UPB Forecast — Price Target — Prediction for 2027 - TradingView
Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage? - Insider Monkey
Enterprise value to EBITDA forward of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
JPMorgan Cuts Upstream Bio Stock Target to Eight Dollars - sekbernews.id
Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026? - Yahoo Finance
Upstream Bio Inc (UPB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
UPB Technical Analysis & Stock Price Forecast - Intellectia AI
Upstream Bio Inc (UPB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Upstream Bio Inc (UPB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Upstream Bio Inc (UPB) Institutional Confidence - TradingKey
Top Executive Makes Strategic Move With Upstream Bio Stock - TipRanks
Upstream Bio Inc (UPB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Upstream Bio Inc (UPB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Upstream Bio Inc (UPB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Upstream Bio Inc (UPB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Upstream Bio Inc (UPB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Upstream Bio presents positive Phase 2 trial data for verekitug By Investing.com - Investing.com Nigeria
Upstream Bio presents positive Phase 2 trial data for verekitug - Investing.com
Upstream Bio, Inc. unveils Phase 2 VIBRANT trial data showing majority of verekitug recipients achieve key improvements - Traders Union
Upstream Bio Reports Positive Phase 2 Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps, Achieving Clinically Meaningful Improvements in Key Symptoms - Quiver Quantitative
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements ... - Caledonian Record
Upstream Bio Presents New Responder Analyses Demonstrating - GlobeNewswire
Upstream Bio Inc. (UPB) Falls 4.39% as Shares Test Key Support LevelGamma Exposure - newsline.com
UPB Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Progress ContinuesEstimate Accuracy - newsline.com
Upstream Bio Cut to Neutral From Overweight by JP Morgan - Moomoo
Upstream Bio lead drug pivotal trial plan follows strong phase 2 data - MSN
JPMorgan Downgrades Upstream Bio to Neutral From Overweight, Cuts Price Target to $8 From $35 - marketscreener.com
JPMorgan downgrades Upstream Bio stock rating on execution risks By Investing.com - Investing.com Australia
J.P. Morgan Downgrades UpStream Bio(UPB.US) to Hold Rating, Announces Target Price $8 - Moomoo
Upstream Bio Shareholders Elect Directors, Ratify 2026 Auditor - The Globe and Mail
Upstream Bio, Inc. leadership to share strategy at major Goldman Sachs event - Traders Union
Upstream Bio (UPB) Declines 3.6%: Support at $6.13 in Focus After Selling PressureParabolic SAR - dars.gov.et
Upstream Bio (UPB) Declines 4% as Shares Approach Key Support at $6.42Thematic ETF Flow - newsline.com
Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026 - markets.businessinsider.com
Upstream Bio to present verekitug trial data at medical congress By Investing.com - Investing.com Australia
Upstream Bio Inc (UPB) 財務データ
収益
当期純利益
現金流量
EPS
Upstream Bio Inc (UPB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sutherland Everett Rand | Chief Executive Officer |
Jun 16 '26 |
Sale |
6.10 |
2,095 |
12,780 |
70,812 |
| Houghton Adam | Chief Business Officer |
Jun 16 '26 |
Sale |
6.10 |
700 |
4,270 |
23,601 |
| Deykin Aaron | Chief Medical Officer |
Jun 16 '26 |
Sale |
6.10 |
895 |
5,460 |
33,197 |
| Ambrose Allison | General Counsel |
Jun 16 '26 |
Sale |
6.10 |
477 |
2,910 |
16,048 |
| GRAY MICHAEL | CFO and COO |
Mar 16 '26 |
Sale |
9.29 |
852 |
7,915 |
29,648 |
| Deykin Aaron | Chief Medical Officer |
Mar 16 '26 |
Sale |
9.29 |
894 |
8,305 |
32,687 |
| Sutherland Everett Rand | Chief Executive Officer |
Mar 16 '26 |
Sale |
9.29 |
2,093 |
19,444 |
72,907 |
| Ambrose Allison | General Counsel |
Mar 16 '26 |
Sale |
9.29 |
475 |
4,413 |
16,525 |
| Houghton Adam | Chief Business Officer |
Mar 16 '26 |
Sale |
9.29 |
699 |
6,494 |
24,301 |
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):